Cipla invests $1.5 million for 14.6% stake in USA’s Chase Pharma

14 May 2014

Indian drugmaker Cipla has said it will acquire a 14.6% stake in US-based Chase Pharmaceuticals for $1.5 million through its wholly owned subsidiary Cipla (EU), UK.

Washington DC-based Chase is an early-stage drug development company focused on developing new approaches for treating Alzheimer's disease. Cipla also said it will make an additional $4.5 million investment in Chase on the achievement of certain milestones.

The Indian drugmaker's investment, through Cipla New Ventures, is part of a syndicate that consists of Edmond de Rothschild Investment Partners and New Rhein Healthcare, the company said in a statement to the Bombay Stock Exchange.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical